Press Releases :: Aurinia Pharmaceuticals Inc. (AUPH)

May 26, 2020 • 6:05 am EDT

Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis

May 15, 2020 • 4:05 pm EDT

Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets’ Virtual Global Healthcare Conference

May 14, 2020 • 4:02 pm EDT

Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights

May 7, 2020 • 6:05 am EDT

Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020

April 27, 2020 • 6:05 am EDT

Aurinia Appoints Joe Miller as Chief Financial Officer

April 20, 2020 • 6:05 am EDT

Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors

March 18, 2020 • 6:05 am EDT

Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings

March 17, 2020 • 6:00 am EDT

Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland

March 16, 2020 • 6:05 am EDT

Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis

March 12, 2020 • 7:00 am EDT

Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative

Select a page:

rss_feed News RSS

©2025 Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23